Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.

Faggiano, A; Di Somma, C; Ramundo, V; Severino, R; Vuolo, L; Coppola, A; Panico, F; Savastano, S; Lombardi, G; Colao, A; Gasperi, M

Faggiano, A; Di Somma, C; Ramundo, V; Severino, R; Vuolo, L; Coppola, A; Panico, F; Savastano, S; Lombardi, G; Colao, A; Gasperi, M.

Affiliation

Faggiano A; IRCCS Fondazione SDN, Via E. Gianturco 113, 80143, Naples, Italy. afaggian@unina.it

Endocrine ; 39(3): 283-7, 2011 Jun.

Article in En | MEDLINE | ID: mdl-21445714

Subject(s)

Alendronate/administration & dosage; Bone Density Conservation Agents/administration & dosage; Bone Density/drug effects; Hypercalcemia/drug therapy; Hyperparathyroidism, Primary/drug therapy; Naphthalenes/administration & dosage; Aged; Aged, 80 and over; Calcium/blood; Cinacalcet; Drug Therapy, Combination; Female; Femur; Humans; Hypercalcemia/etiology; Hyperparathyroidism, Primary/blood; Hyperparathyroidism, Primary/complications; Lumbar Vertebrae; Male; Middle Aged; Parathyroid Hormone/blood; Retrospective Studies

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Density / Alendronate / Hyperparathyroidism, Primary / Bone Density Conservation Agents / Hypercalcemia / Naphthalenes Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Endocrine Year: 2011 Document type: Article

Fulltext

XML

PubMed Links

Search on Google